OMEROS CORP (OMER) Borrowing debt
- Total debt · latest quarter (USD): Value (m); Formula and calculation Current and noncurrent long-term debt plus complete reported short-term borrowings (commercial paper alone when no complete total is admitted). Period ending 2019-03-31..
- Net cash · latest quarter: Value (m); Formula and calculation Cash and cash equivalents plus current marketable securities less interest-bearing debt; negative net cash is displayed as net debt. Period ending 2019-03-31..
- Debt / assets · latest quarter: Value (m); Formula and calculation Current and noncurrent long-term debt plus complete reported short-term borrowings (commercial paper alone when no complete total is admitted) / total assets. Period ending 2019-03-31..
Borrowing debt
Overview →Financial period ending 2019-03-31; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Total debt · latest quarter (USD) | (m) | Current and noncurrent long-term debt plus complete reported short-term borrowings (commercial paper alone when no complete total is admitted). Period ending 2019-03-31. Calculation unavailable: missing inputs remain (m). |
| Net cash · latest quarter | (m) | Cash and cash equivalents plus current marketable securities less interest-bearing debt; negative net cash is displayed as net debt. Period ending 2019-03-31. Calculation unavailable: missing inputs remain (m). |
| Debt / assets · latest quarter | (m) | Current and noncurrent long-term debt plus complete reported short-term borrowings (commercial paper alone when no complete total is admitted) / total assets. Period ending 2019-03-31. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Borrowing debt due within one year | 2.56M USD | Long-term Debt, Current Maturities |
| Borrowing debt due after one year | (m) | Long-term Debt, Excluding Current Maturities |
| Commercial paper | (m) | |
| Cash and current securities | (m) | Cash and Cash Equivalents, at Carrying Value · Debt Securities, Available-for-sale, Current |
| Borrowing debt | (m) | Long-term Debt, Current Maturities · Long-term Debt, Excluding Current Maturities |
| Total assets | 101.25M USD | Assets |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Total debt | Net cash / debt | Borrowing debt due within one year (USD) | Borrowing debt due after one year (USD) | Commercial paper (USD) | Cash and current securities (USD) | Total assets (USD) | Debt / assets |
|---|---|---|---|---|---|---|---|---|
| 2019-03-31 | (m) | (m) | $2.56M | (m) | (m) | (m) | $101.25M | (m) |
| 2018-12-31 | (m) | (m) | $889.00K | (m) | (m) | (m) | $95.94M | (m) |
| 2018-09-30 | (m) | (m) | $560.00K | $131.69M | (m) | (m) | $75.61M | (m) |
| 2018-06-30 | (m) | (m) | $608.00K | $129.75M | (m) | (m) | $106.35M | (m) |
| 2018-03-31 | (m) | (m) | $513.00K | $85.04M | (m) | (m) | $89.03M | (m) |
| 2017-12-31 | (m) | (m) | $490.00K | $84.12M | (m) | (m) | $116.33M | (m) |
| 2017-09-30 | (m) | (m) | $368.00K | $82.78M | (m) | (m) | $125.52M | (m) |
| 2017-06-30 | (m) | (m) | $250.00K | $81.51M | (m) | (m) | $60.35M | (m) |
| 2017-03-31 | (m) | (m) | $228.00K | $80.50M | (m) | (m) | $58.40M | (m) |
| 2016-12-31 | (m) | (m) | $198.00K | $79.51M | (m) | (m) | $67.28M | (m) |
| 2016-09-30 | (m) | (m) | $190.00K | $70.29M | (m) | (m) | $72.76M | (m) |
| 2016-06-30 | (m) | (m) | $193.00K | $69.83M | (m) | (m) | $46.11M | (m) |
| 2016-03-31 | (m) | (m) | $69.00K | $49.97M | (m) | (m) | $35.97M | (m) |
| 2015-12-31 | (m) | (m) | $73.00K | $49.77M | (m) | (m) | $48.99M | (m) |
| 2015-09-30 | (m) | (m) | $9.58M | $18.97M | (m) | (m) | $41.42M | (m) |
| 2015-06-30 | (m) | (m) | $9.29M | $21.48M | (m) | (m) | $58.64M | (m) |
| 2015-03-31 | (m) | (m) | $9.02M | $23.91M | (m) | (m) | $74.91M | (m) |
| 2014-12-31 | (m) | (m) | $6.45M | $26.26M | (m) | (m) | $11.09M | (m) |
| 2014-09-30 | (m) | (m) | $3.99M | $28.55M | (m) | (m) | $25.29M | (m) |
| 2014-06-30 | (m) | (m) | $1.61M | $30.76M | (m) | (m) | $40.99M | (m) |
| 2014-03-31 | (m) | (m) | $0.00 | $32.21M | (m) | (m) | $56.07M | (m) |
| 2013-12-31 | (m) | (m) | $5.60M | $14.90M | (m) | (m) | $16.54M | (m) |
| 2013-09-30 | (m) | (m) | $4.02M | $16.38M | (m) | (m) | $12.01M | (m) |
| 2013-06-30 | (m) | (m) | $2.48M | $17.81M | (m) | (m) | $23.06M | (m) |
| 2013-03-31 | (m) | (m) | $997.00K | $19.20M | (m) | (m) | $17.69M | (m) |
| 2012-12-31 | (m) | (m) | (m) | $20.10M | (m) | (m) | $26.57M | (m) |
| 2011-12-31 | (m) | (m) | $5.89M | $13.55M | (m) | (m) | $26.98M | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| Oric Pharmaceuticals, Inc. (ORIC) | United States | $1.367B | -8.00 |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| Kardigan, Inc. (KARD) | United States | $1.346B | |
| Tyra Biosciences, Inc. (TYRA) | United States | $1.337B | -12.83 |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |